# EDGAR Filing Document

**Accession Number:** 0001563577
**File Stem:** 0001123292-26-000772
**Filing Date:** 2026-5
**Character Count:** 8716
**Document Hash:** b7cc4abb31e08283abe508db6d41efaa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001123292-26-000772.hdr.sgml**: 20260529

**ACCESSION NUMBER**: 0001123292-26-000772

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260515

**FILED AS OF DATE**: 20260529

**DATE AS OF CHANGE**: 20260529

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Opler Timothy
- **CENTRAL INDEX KEY:** 0001706867

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39114
- **FILM NUMBER:** 261045655

**MAIL ADDRESS:**
- **STREET 1:** C/O EMERALD BIOVENTURES, LLC
- **STREET 2:** 555 MADISON AVENUE, SUITE 11D
- **CITY:** NEW YORK
- **STATE:** NY
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Emerald Bioventures, LLC
- **CENTRAL INDEX KEY:** 0002020620

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39114
- **FILM NUMBER:** 261045656

**BUSINESS ADDRESS:**
- **STREET 1:** C/O EMERALD BIOVENTURES, LLC
- **STREET 2:** 555 MADISON AVENUE, SUITE 11D
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** (332) 237-4447

**MAIL ADDRESS:**
- **STREET 1:** C/O EMERALD BIOVENTURES, LLC
- **STREET 2:** 555 MADISON AVENUE, SUITE 11D
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Galera Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001563577
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 461454898
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 101 LINDENWOOD DRIVE
- **STREET 2:** SUITE 225
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
- **BUSINESS PHONE:** 610-725-1500

**MAIL ADDRESS:**
- **STREET 1:** 101 LINDENWOOD DRIVE
- **STREET 2:** SUITE 225
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Emerald Bioventures, LLC<br><sub>(Last) (First) (Middle)</sub><br>555 MADISON AVENUE, SUITE 11D<br><sub>(Street)</sub><br>NEW YORK, NY 10022<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-15 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Galera Therapeutics, Inc. [ GRTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Opler Timothy<br><sub>(Last) (First) (Middle)</sub><br>555 MADISON AVENUE, SUITE 11D<br><sub>(Street)</sub><br>NEW YORK, NY 10022<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-15 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Galera Therapeutics, Inc. [ GRTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-05-15 |  | C |  | 20813818<sup>(1)</sup> | A | <sup>(3)</sup> | 61029978 | D<sup>(2)</sup> |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Series B Preferred Stock | <sup>(3)</sup> | 2026-05-15 |  | C |  |  | 20813.8186<sup>(1)</sup> | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 20813818 | <sup>(3)</sup> | 0 | D<sup>(2)</sup> |  |

---

### Footnotes:

(1) Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock, as amended ("Certificate of Designation"), no fractional shares were issued upon conversion. In lieu of fractional shares, the Issuer will pay Emerald Bioventures, LLC ("Emerald") an amount in cash equal to the trading value of such fractional shares as of the close of business on the date of the conversion in accordance with the Certificate of Designation.

(2) This Form 4 is jointly filed by and on behalf of each of Emerald and Timothy Opler. Emerald is the record and direct beneficial owner of the securities reported herein. Mr. Opler is the managing member of Emerald and may be deemed to beneficially own securities owned by Emerald.

(3) Represents 20,813.8186192892 shares of the Issuer's Series B Non Voting Convertible Preferred Stock (the "Series B Preferred Stock"). On May 15, 2026, the Issuer converted all outstanding Series B Preferred Stock into a number of shares of the Issuer's Common Stock ("Common Stock") calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock issuable upon the conversion of each share of Series B Preferred Stock), pursuant to and in accordance with the Certificate of Designation. The shares of Series B Preferred Stock have no expiration date.

**Signature:** /s/ Timothy Opler, Managing Member  
**Date:** 2026-05-29

**Signature:** /s/ Timothy Opler  
**Date:** 2026-05-29

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**